Our unique industry solution connects stakeholders in the Cell & Gene Therapy value chain, enabling manufacturers, supply chain partners and Healthcare Providers (HCPs), to work in a harmonized, standardized way.
Multi-tenant by design, the purposeful architecture of INTIENT Unify Cell & Gene orchestrates patient enrollment, reduces cost and the potential risks of therapy coordination—improving time-to-therapy.
Until now, manufacturers have worked on this problem independently. The multitude of solutions frustrates both access and affordability for HCPs. Teaming with Life Sciences industry leaders, we reimagined and redesigned the interactions between the stakeholders across the Cell & Gene value chain to create a streamlined experience. INTIENT Unify delivers a consistent experience in a secured application.
Advancing Cell & Gene therapies
Advancing Cell & Gene Therapies: Dr. Khalid Shah
Accenture INTENT Summit Video Cell and Gene Therapy Luminary Speaker
INTIENT drives interaction, not just integration. With our solution, treatment centers for Cell & Gene Therapies interact directly with the manufacturers who are creating the patient-specific treatment. This consistent experience may be deployed for clinical trials and real-world commercial use.
Enabling streamlined interactions between healthcare providers and manufacturers, reducing administrative burden, cost, and improving time-to-therapy.
GxP and HIPAA compliant, safeguarding the privacy of patient data and manufacturer intellectual property.
Configurable for clinical and commercial therapies and modalities. Modular deployment supports developers at different stages in their CGT lifecycle.
Insights from our experts to help pharmaceutical, biotechnology, med-tech, and consumer health companies improve patient outcomes.